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The early cardiac physiologists discovered that depriving the heart 
of its blood supply led to an acceleration of glycolysis which could 
provide anaerobic energy. Richard Bing1 in the 1950s used the novel 
tool of coronary sinus catheterisation to study the energy sources 
of human heart muscle in patients with heart failure. He showed 
that for its energy sources the heart uses mostly fatty acids and to a 
lesser extent glucose. Circulating free-fatty acids (FFA) could inhibit 
myocardial glucose oxidation.2 In 1962 Sodi-Pallares et al.3 launched 
the concept of metabolic therapy using glucose-insulin-potassium 
(GIK) solutions that reduced acute electrocardiographic signs of 
ischaemic damage. 
The mechanism whereby GIK provides benefit is in part by 
reducing the toxic high FFA levels that are found in early acute 
myocardial infarction (AMI) as a result of major catecholamine 
stimulation with acute adipose tissue lipolysis (Fig. 1).4,5 In heart 
failure (HF), beta-blockade and GIK also reduce circulating FFA, 
while the newer drugs trimetazidine and ranolazine act metabolically 
to improve the condition of patients with ischaemia or HF.6
Metabolic therapy must be given early 
Almost all of the prior GIK studies for patients with acute coronary 
syndromes (ACS) started infusions far too late after the onset of 
symptoms. During the critical first hour, GIK infusions could 
potentially reduce major energy depletion. Crucial experimental 
support for this concept came from relevant work at the University 
of Cape Town (UCT) supported by the Chris Barnard Fund,7 
thus supporting the rationale for the positive IMMEDIATE 
study in which GIK was infused by paramedics to patients in the 
prehospital emergency ambulance setting.8 Started immediately 
after the onset of symptoms, and continued thereafter, GIK 
reduced by 40% the rate of the combined cardiovascular endpoint, 
cutting in-hospital mortality or cardiac arrest by half, besides 
reducing infarct size measured at 30 days.8 
Molecular cardioprotection
The extraordinary complexity of the molecular protective pathways 
must, like the metabolic paths, have evolved millions of years ago 
when rapid cardioprotection was required after the hyperadrenergic 
stresses and blood losses experienced when hunting and escaping 
from wild animals.9
Today these paths can be brought into action during prompt 
therapy for acute coronary occlusion by rapid reperfusion, as in AMI. 
Although saving many cells otherwise threatened with ischaemic cell 
death, rapid reperfusion kills a significant percentage of cells that 
could have been saved by the appropriate intervention. Indeed, the 
time has come to take reperfusion injury seriously!10
Reperfusion damage, with the sudden return of oxygen and 
reversal of tissue pH changes, is inevitable during the optimal therapy 
of AMI by prompt percutaneous coronary intervention (PCI). 
Working on this problem, the group of Hausenloy and Yellon10 in 
London discovered the RISK (Reperfusion Injury Salvage Kinases) 
cardioprotective pathway. Of major interest is that metabolic and 
molecular protection can go hand in hand. That concept leads to 
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Fig. 1. Metabolic cardioprotection during acute coronary syndromes (ACS) 
hinges on reduction of circulating free-fatty acids (FFA) both by beta-
blockade and by infusion of glucose-insulin-potassium (GIK).8 Thereby 
protective glycolytic metabolism by the ischaemic tissue is promoted. 
The harm of FFA is exerted by increasing tissue fatty acids acyl CoA and 
carnitine, thereby promoting membrane damage and lethal arrhythmias. 
TG = tissue triglycerides.
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the proposal that insulin therapy, a promoter of optimal cardiac 
metabolic protection, can directly promote cardiac cell survival 
during reperfusion.11
From the evolutionary point of view it would have been inadequate 
to have only one molecular cardioprotective path. Thus another 
path was discovered, namely the SAFE (Survival Activating Factor 
Enhancement) pathway, that is the focus of our group under Sandrine 
Lecour.12 This path involves cytokine protection by low levels of 
tumour necrosis factor-alpha (TNF-α) acting on a specific series of 
molecular events and leading to activation of transcription factor 
signal transducer and activator of transcription-3 (STAT-3). 
The jump from experiments to 
clinical certainty
Postconditioning by balloon inflation-reflation 
Can the basic laboratory data be clinically applied? In animals such as 
the baboon, the major part of myocardial metabolic damage occurs in 
the first hour.7 The first human studies with early intervention were 
with ischaemic postconditioning. That means that after coronary flow 
had been abruptly restored to the previously ischaemic myocardium 
by PCI, the intra-coronary balloon was blown up again to cause 
temporary ischaemia. The balloon was then released only to be 
briefly blown up again, a procedure repeated for five cycles, thereby 
causing a very significant reduction in infarct size as in the basic 
observations made by Thibault et al.13 With late reperfusion, after 
the crucial first 3 hours, the extent of reperfusion damage can be 
expected to be slight and the benefit of therapy aimed at reperfusion 
damage likewise slight or totally absent.
Remote conditioning 
An even more interesting approach is remote conditioning, whereby 
intermittent occlusion-reperfusion of a limb acts at a distance to 
reduce cardiac reperfusion damage. First shown in patients with 
coronary bypass operations by Yellon’s group, the concept has now 
been widely extended to involve other organs such as kidney and 
brain. This approach has found human application by the simple 
procedure of pumping up and down an ordinary blood pressure 
sphygmomanometer in the ambulance taking patients to hospital.14 
The primary endpoint was myocardial salvage index at 30 days 
after primary PCI, measured, by myocardial perfusion imaging, 
as the proportion of the area at risk of cell death but salvaged by 
treatment. The area saved from cellular death was about 20 - 25%. 
This procedure has no known side-effects and reduced the extent 
of the infarcted tissue; benefit was seen even in infarcts sustained by 
patients who were very rapidly transferred to the emergency room 
for PCI, following the onset of symptoms, by the efficient ambulance 
service that Denmark enjoys. The vexing question of how remote 
ischaemic conditioning works (cardioprotection at a distance) is 
still a matter of dispute; there are arguments for both humoral and 
nervous mechanisms. 
From near-certainty to wishful 
thinking
Wouldn’t it be wonderful if we could imagine that certain foodstuffs 
or beverages contain protective agents that promote our molecular 
ischaemic pathways? Although this is fanciful, nonetheless there is 
a possibility that certain components of wine, namely resveratrol 
and melatonin, may protect during reperfusion injury during the 
therapy of heart attacks. The impact on myocardial infarct size 
after coronary occlusion and reperfusion following administration 
of red wine, resveratrol, and melatonin to rats has been examined 
in our laboratory.15 Both resveratrol and melatonin gave substantial 
protection. The group of Sandrine Lecour has in the past suggested 
that the resveratrol content of red wine may, with only modest intake, 
reach blood levels high enough to be cardioprotective although 
that conclusion is only inferential and hypothetical. More recently 
melatonin has been discovered in red wine and also in white.15  
Melatonin is commonly used by persons threatened by jet lag during 
air travel because it promotes a natural sleep rhythm (and may be one 
of the reasons why red wine with meals goes with a good night’s sleep). 
Speculatively, red wine16 is part of the French paradox with, 
however, many other factors contributing to the relative protection 
from myocardial infarction that the French enjoy, because of their 
traditional lifestyle (which regretfully is now fading). Overall, modest 
wine intake is of itself no panacea but rather only a small part of part 
of the healthy five-point lifestyle in which non-smoking and daily 
vigorous exercise, for more than 30 minutes, are the two top criteria.17 
As fully argued in my recent book, Living Longer, Living Better,18 
intense exercise not only acts by promoting preponderance of the 
vagus anti-adrenergic protective nervous system at rest, but also by 
stimulating the protective molecular paths. 
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